Alexander Belcredi

Managing Director
BioNTech R&D Austria

Alexander Belcredi has been working in the pharmaceutical space for over a decade. He spent nine years at the Boston Consulting Group (BCG) where he was part of the global Healthcare team, focusing on Pharma and Medtech. While at BCG, Alexander became acutely aware of the urgent need to develop alternatives to antibiotics and was fascinated by the role that phage therapy can play. In 2017, he co-founded PhagoMed Biopharma GmbH, a biotech company developing phage-based pharmaceuticals to treat bacterial infections. After the successful exit to BioNTech in 2021, Alexander now leads BioNTech Austria as Managing Director. Alexander holds an MA in Modern History and Economics from the University of St. Andrews as well as an MBA from INSEAD.